SKF 83822 hydrobromide
High affinity, selective dopamine D1-like receptor agonist. Ki values are 3.2, 3.1, 186, 66, 335, 1167, 1251 and 1385 nM at recombinant D1, D5, D2, D3, D4, 5-HT2A, α1A and α1B receptors respectively. Stimulates adenylyl cyclase (EC50 = 65 nM) but not phosphoinositide hydrolysis. Induces extreme arousal and hyperlocomotion following subcutaneous administration in monkeys.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 424.76. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.35 mL||11.77 mL||23.54 mL|
|5 mM||0.47 mL||2.35 mL||4.71 mL|
|10 mM||0.24 mL||1.18 mL||2.35 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
References are publications that support the products' biological activity.
Undie et al (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J.Neurochem. 62 2045 PMID: 7908949
Peacock and Gerlach (2001) Aberrant behavioural effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions. Biol.Psychiatry 50 501 PMID: 11600103
O'Sullivan et al (2004) SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled D1-like receptors: behavioural topography. Eur.J.Pharmacol. 486 273 PMID: 14985049
If you know of a relevant reference for SKF 83822 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: SKF 83822 hydrobromide, supplier, Selective, D1-like, agonists, Dopamine, D1, Receptors, D5, dopaminergic, SKF83822, hydrobromide, D1, and, D5, Receptors, D1, and, D5, Receptors, Tocris Bioscience
3 Citations for SKF 83822 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 83822 hydrobromide include:
Urizar et al (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Neuropsychopharmacology 7 624 PMID: 21785426
Kramar et al (2014) Dopamine in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory. J Neurosci 39 1645 PMID: 24442095
Ruskin et al (2013) Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One 8 e65021 PMID: 23755170
Do you know of a great paper that uses SKF 83822 hydrobromide from Tocris? If so please let us know.
Reviews for SKF 83822 hydrobromide
There are currently no reviews for this product. Be the first to review SKF 83822 hydrobromide and earn rewards!
Have you used SKF 83822 hydrobromide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.